Mark Mayson, MD
Pulmonary Disease · Columbia, SCNPI 1962480889
Payments from drug & device makers
Across 714 payments — averaging $119.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$73K
- Sanofi$2K
- GSK$2K
- Insmed, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$863
- Actelion Pharmaceuticals US, Inc.$819
- plus $6K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 188 | $72,580 |
| Sanofi | 40 | $2,255 |
| GSK | 96 | $1,590 |
| Insmed, Inc. | 47 | $1,046 |
| Regeneron Healthcare Solutions, Inc. | 26 | $863 |
| Actelion Pharmaceuticals US, Inc. | 29 | $819 |
| United Therapeutics Corporation | 26 | $759 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $713 |
| Merck | 28 | $567 |
| Electromed, Inc. | 36 | $550 |
| Boehringer Ingelheim | 26 | $454 |
| Gilead | 19 | $410 |
| Novartis | 10 | $363 |
| Verona Pharma, Inc. | 19 | $294 |
| Advanced Respiratory, Inc | 10 | $263 |
| Amgen | 11 | $240 |
| Mylan Specialty L.p. | 11 | $224 |
| Baxter Healthcare | 9 | $212 |
| Bayer | 1 | $200 |
| Genentech USA, Inc. | 4 | $190 |
| Philips North America LLC | 10 | $158 |
| Genentech, Inc. | 1 | $150 |
| ANI Pharmaceuticals, Inc. | 8 | $145 |
| Grifols USA, LLC | 4 | $89 |
| La Jolla Pharmaceutical Company | 4 | $75 |
| Viatris Specialty LLC | 3 | $62 |
| AbbVie | 3 | $55 |
| Paratek Pharmaceuticals, Inc. | 3 | $52 |
| Vifor Pharma, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $33 |
| Shionogi Inc | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Melinta Therapeutics, LLC | 1 | $22 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $17 |
| Beckman Coulter, Inc. | 1 | $17 |
How this compares
$85,574 in reported general payments places this provider in the 85th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Columbia
- Gregory FeldmanColumbia$15.1M
- Richard BoganColumbia$4.8M
- Laura HerpelColumbia$442K
- Abhinav GuptaColumbia$310K
- Christopher PerryColumbia$145K
- Karla Cruz MorelColumbia$113K
- Jake KriegmdColumbia$112K
- Carlton CauthenColumbia$22K
- Liang ZhaColumbia$10K
- Todd GandyColumbia$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.